The agonists of formyl peptide receptors prevent development of severe sepsis after microbial infection

Area of Science:

• Immunology
• Microbiology
• Pharmacology

Background:

• Severe sepsis is a leading cause of death in intensive care units.
• Sepsis results from a failure of host immune defenses against microbial invasion.
• Formyl peptide receptors (FPRs) are key mediators of immune responses to microbial products.

Purpose of the Study:

• To investigate the protective effects of formyl peptide receptor agonists, specifically WKYMVm, against severe sepsis.
• To elucidate the mechanisms underlying the protective effects of WKYMVm in a sepsis model.

Main Methods:

• A cecal ligation and puncture (CLP) sepsis mouse model was used.
• Administration of WKYMVm was evaluated for its effects on survival, bactericidal activity, organ inflammation, and immune cell apoptosis.
• Cytokine production (IFN-γ, IL-12, IL-17, TGF-β, TNF-α, IL-1β, IL-6) and T helper cell responses were assessed.
• Experiments were conducted in wild-type, IFN-γ-deficient, and IL-17-deficient mice.

Main Results:

• WKYMVm administration significantly protected against death in the CLP sepsis model.
• WKYMVm enhanced bactericidal activity and inhibited vital organ inflammation and immune cell apoptosis.
• WKYMVm modulated cytokine production, enhancing type 1 (IFN-γ, IL-12) and type 17 (IL-17, TGF-β) cytokines while inhibiting pro-inflammatory cytokines (TNF-α, IL-1β, IL-6).
• The therapeutic effects were partly dependent on IFN-γ and IL-17, indicating a role for type 1 and type 17 immune responses.

Conclusions:

• Peptide agonists of formyl peptide receptors, such as WKYMVm, are effective in preventing severe sepsis.
• The protective mechanism involves the augmentation of type 1 and type 17 immune responses.
• FPR agonists represent a potential therapeutic strategy for managing sepsis.